InvestorsHub Logo
Followers 1
Posts 407
Boards Moderated 0
Alias Born 07/20/2006

Re: DewDiligence post# 1827

Wednesday, 09/12/2007 9:05:58 AM

Wednesday, September 12, 2007 9:05:58 AM

Post# of 3757
How is one to interpret the data given HBV's accelerated incidence along with theoretical increased diagnosis and in light of the 2005 (Baraclude) vs. 2007 (Tyzeka) total scripts? It would seem that total scripts would be greater but Baraclude is entrenched.
Is it possible to see a dent in Baraclude sales since Tyzeka has become available? I mean, is Tyzeka a problem for Baraclude or are their sales increasing at a consistent rate irrespective of Tyzeka. Thanks